Sugi Predict

Sugi Predict / Targets / GOPC

GOPC

Golgi-associated PDZ and coiled-coil motif-containing protein · Q9HD26 · GOPC on Sugi Atlas →

7,597 patent compounds predicted against GOPC, 5,089 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2239169 SCHEMBL2239169 1.00 5/20
SCHEMBL2241344 SCHEMBL2241344 0.85 5/20
SCHEMBL1428457 SCHEMBL1428457 0.80 5/20
SCHEMBL2245013 SCHEMBL2245013 0.75 5/20
SCHEMBL2239992 SCHEMBL2239992 0.64 5/20
SCHEMBL2239398 SCHEMBL2239398 0.82 4/20
SCHEMBL2243189 SCHEMBL2243189 0.70 4/20
SCHEMBL2240877 SCHEMBL2240877 0.68 4/20
SCHEMBL2238773 SCHEMBL2238773 0.67 4/20
SCHEMBL2239514 SCHEMBL2239514 0.52 3/20
SCHEMBL2243188 SCHEMBL2243188 0.50 3/20
SCHEMBL1561830 SCHEMBL1561830 0.40 3/20
SCHEMBL1562255 SCHEMBL1562255 0.40 3/20
SCHEMBL2463312 SCHEMBL2463312 0.72 2/20
SCHEMBL2241113 SCHEMBL2241113 0.69 2/20
SCHEMBL2239440 SCHEMBL2239440 0.68 2/20
SCHEMBL2244145 SCHEMBL2244145 0.66 2/20
SCHEMBL477393 SCHEMBL477393 0.63 2/20
SCHEMBL477633 SCHEMBL477633 0.63 2/20
SCHEMBL2601115 SCHEMBL2601115 0.63 2/20

Clinical trials — most relevant to GOPC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
SCARFREE-001: Verteporfin for Scar Prevention PHASE2NOT_YET_RECRUITING
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Gene Expression in Inflammatory Bowel Disease nanENROLLING_BY_INVITATION
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN) nanRECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Brain Involvement in Dystrophinopathies Part 2 nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study nanCOMPLETED
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Profiling Gingival Crevicular Fluid β-Catenin Level With 8-OHdG and Total Antioxidants Capacity During Healing of Periodontal Pockets: A 3-month Clinical Trial nanNOT_YET_RECRUITING
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer nanCOMPLETED
Evaluation of the Clinical Course of NERD and Assessment of the Esophageal Mucosa Resistance nanACTIVE_NOT_RECRUITING
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
Genetic Study of Patients With Primary Ciliary Dyskinesia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GOPC binder may also engage these)

ProteinNameSimilarity
Q5RD32 — 1.000 Q5RD32 →
Q8BH60 — 1.000 Q8BH60 →
Q8TDM6 — 0.990 Q8TDM6 →
Q9Z136 — 0.989 Q9Z136 →
Q99KF0 — 0.989 Q99KF0 →
Q02225 — 0.988 Q02225 →
Q5F488 — 0.987 Q5F488 →
Q6ZWJ1 — 0.987 Q6ZWJ1 →
Q91Z80 — 0.987 Q91Z80 →
Q8C2K1 — 0.987 Q8C2K1 →
Q62796 — 0.987 Q62796 →
Q99LE1 — 0.987 Q99LE1 →
E9Q9R9 — 0.986 E9Q9R9 →
Q9H4E7 — 0.986 Q9H4E7 →
Q99LJ0 — 0.986 Q99LJ0 →
Q9WV89 — 0.986 Q9WV89 →
Q9EP53 — 0.986 Q9EP53 →
Q4V872 — 0.986 Q4V872 →
Q812E4 — 0.986 Q812E4 →
Q8BMA3 — 0.986 Q8BMA3 →
Q7SYB5 — 0.986 Q7SYB5 →
A0M8T5 — 0.986 A0M8T5 →
Q86YS3 — 0.986 Q86YS3 →
Q9ULJ8 — 0.986 Q9ULJ8 →
A1A5G4 — 0.986 A1A5G4 →
A0PJT0 — 0.986 A0PJT0 →
Q0V989 — 0.985 Q0V989 →
Q69ZZ6 — 0.985 Q69ZZ6 →
Q0P4J3 — 0.985 Q0P4J3 →
Q9EQJ9 — 0.985 Q9EQJ9 →